The biobank of hope

Samples of the PROCURE Biobank has allowed the realization of a project whose results are published in the prestigious scientific journal Cell

It is with pride that we announce that the first provision of biological tissue samples provided to the US National Human Genome Research Institute has allowed the realization of a project on the characterization and full analysis of the prostate cancer genome. Published in the prestigious scientific journal Cell on November 5, the full analysis of 333 prostate cancers identified key genetic alterations that can help improve the classification and treatment of the disease.

Of the 26 institutions asked to provide samples (Harvard, MD Anderson, Memorial Sloan-Lettering Cancer Center), the PROCURE Biobank has risen in sixth position for the number of samples available for the project, and received recognition for their high quality as well. Quite an achievement for our biobank. To learn more about the results of this study, click here.

Promising drug combination for advanced prostate cancer

Montreal: A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.

Antonio Paris, 59, is one of the patients participating in the CRCHUM. “Since I started the new treatment 14 months ago, my cancer first remitted and now is stable,” he said. Read more.

Reference: MNT |Published on November 26, 2015

Oakville biochemist developing new DNA test to better detect prostate cancer

An Oakville clinical biochemist is developing an innovative DNA test to better detect prostate cancer and reduce the number of biopsies needed. Read more.

Reference: Oakville Beaver | Published on December 5, 2015